Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Dominic J. Ambrosi"'
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Table S1: ABT-165 binding affinity; Table S2: ABT-165 in vitro potency; Table S3: Effect of VEGF on anti-DLL4 cellular potency of ABT-165; Table S4: Summary of in vivo efficacy; Table S5: Key safety findings of ABT-487 and ABT-165; Figure S1: Serum c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948fdfba3f05b8a422e19034176fe36d
https://doi.org/10.1158/1535-7163.22505686
https://doi.org/10.1158/1535-7163.22505686
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
This file describes the binding assay details of surface plasmon resonance technology, ligand and receptor binding competition assays, western blot detection of DLL4 protein down-regulation, and the methods to measure total circulating soluble DLL4 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267ca9367d459176dea46bdd55158c64
https://doi.org/10.1158/1535-7163.22505689.v1
https://doi.org/10.1158/1535-7163.22505689.v1
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2454e519448df5024c51607be68974ce
https://doi.org/10.1158/1535-7163.c.6538150.v1
https://doi.org/10.1158/1535-7163.c.6538150.v1
Autor:
Susan E. Morgan-Lappe, Wenqing Gao, Enrico L. Digiammarino, Yingchun Li, Surekha S. Akella, Sanjay C. Panchal, Jonathan Hickson, Sarah R. Mudd, Louie Naumovski, Jijie Gu, Ralston Sherry L, Dominic J. Ambrosi, Catherine Zhang, Kelly Foster-Duke, Lucia Eaton, Fang Jiang, Deanna L. Haasch
Publikováno v:
Molecular Cancer Therapeutics. 17:1039-1050
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Autor:
Sahana Bose, Dominic J. Ambrosi, Tariq Ghayur, Rajesh V. Kamath, Chung-Ming Hsieh, Susan E. Lacy, Donna Conlon, Chengbin Wu, Edit Tarcsa, Ravi Chari, Renee Miller
Publikováno v:
mAbs
Interleukin-1 (IL-1) cytokines such as IL-1α, IL-1β, and IL-1Ra contribute to immune regulation and inflammatory processes by exerting a wide range of cellular responses, including expression of cytokines and chemokines, matrix metalloproteinases,
Autor:
Yingchun Li, Wenqing Gao, Fang Jiang, Lucia Eaton, Surekha S. Akella, Deanna L. Haasch, Jonathan A. Hickson, Jijie Gu, Ralston Sherry L, Kelly Foster-Duke, Dominic J. Ambrosi, Susan Morgan-Lappe
Publikováno v:
Cancer Research. 76:867-867
The first generation anti-angiogenic drugs designed to block the VEGF/VEGFR pathway lend modest clinical benefit for cancer patients. Other than VEGF, DLL4 is the only known angiogenic factor with a haploinsufficiency phenotype, underscoring its esse
Autor:
Dominic J. Ambrosi, Craig E. Nelson, Winfried Krueger, Theodore P. Rasmussen, Caroline M. Jakuba, Eric S Veilleux, Evan Barry
Publikováno v:
Stem cells (Dayton, Ohio). 27(7)
Mouse embryonic stem cells (ESCs) proliferate with rapid cell cycle kinetics but without loss of pluripotency. The histone methyltransferase Dot1L is responsible for methylation of histone H3 at lysine 79 (H3K79me). We investigated whether ESCs requi
Autor:
Theodore P. Rasmussen, Rachel J. O’Neill, Craig Obergfell, Anupinder Kaur, Winfried Krueger, Dominic J. Ambrosi, Borko Tanasijevic
Publikováno v:
Stem cells (Dayton, Ohio). 25(5)
Recent experiments demonstrate that somatic nuclei can be reprogrammed to a pluripotent state when fused to ESCs. The resulting hybrids are pluripotent as judged by developmental assays, but detailed analyses of the underlying molecular-genetic contr
Advances in mammalian cloning prove that somatic nuclei can be reprogrammed to a state of totipotency by transfer into oocytes. An alternative approach to reprogram the somatic genome involves the creation of hybrids between somatic cells and other c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e95bcf6adb10c9110e82b832e8c2b2b
https://europepmc.org/articles/PMC6740314/
https://europepmc.org/articles/PMC6740314/
Autor:
Barry, Evan R., Krueger, Winfried, Jakuba, Caroline M., Veilleux, Eric, Ambrosi, Dominic J., Nelson, Craig E., Rasmussen, Theodore P.
Publikováno v:
Stem Cells; Jul2009, Vol. 27 Issue 7, p1538-1547, 10p, 1 Color Photograph, 1 Chart, 5 Graphs